(Reuters) - Emergent BioSolutions Inc said the U.S. Food and Drug Administration approved its treatment for inhaled anthrax, triggering a $7 million milestone payment from the U.S. Department of Health and Human Services (HHS). Emergent Bio developed the treatment, Anthrasil, as part of a $160 million contract it signed in 2005 with the Biomedical Advanced Research and Development Authority (BARDA), a part of the HHS. The drug is already being stored in the U.S. Strategic National Stockpile, the company said on Wednesday. Anthrasil is a sterile solution of purified human immune globulin G (IgG) that targets the anthrax toxins of Bacillus anthracis, the bacteria that causes anthrax disease. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment